Total and H‐specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration

Documenti analoghi

• Apolipoprotein CIII correlates with lipoproteins in the fed state and is not regulated by leptin administration in states of hypoleptinemia induced by acute or chronic energy deficiency: Results from two randomised controlled trials
  di: Arantxa Ramirez‐Cisneros, et al.
  Pubblicazione: (2025)
• Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin–activin–follistatin– IGF ‐1 axis: Results from an exploratory, randomized, placebo‐controlled, crossover study
  di: Valeria Gutierrez de Piñeres, et al.
  Pubblicazione: (2025)
• Characterization of the effect of naltrexone/bupropion on body composition
  di: Vanessa Tardio, et al.
  Pubblicazione: (2025)
• Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial
  di: Alina N. Saidi, et al.
  Pubblicazione: (2025)
• The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials
  di: Rachelle Haber, et al.
  Pubblicazione: (2024)